Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2019-06-08 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2019-06-08 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, specifically a Definitive Additional Materials supplementing a Proxy Statement for Ligand Pharmaceuticals' 2019 Annual Meeting of Stockholders. It discusses updates to the nominating and corporate governance committee's policies and procedures, including diversity considerations for director nominations. The content focuses on governance and board-related information rather than financial results or other report types. The presence of 'Proxy Statement' and detailed governance committee information aligns with the Proxy Solicitation & Information Statement category. The document is not a full Annual Report, Earnings Release, or Management Discussion, nor is it a simple announcement or certification. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2019-06-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 31, 2019, by Ligand Pharmaceuticals Incorporated. It reports a specific event: the execution and delivery of a license agreement with GigaGen, Inc. The content focuses on the description of the license agreement and related business details. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is a current report on a material event rather than a financial report or earnings release. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2019-06-03 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-01 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.